Groupe la Francaise Takes $5.17 Million Position in CVS Health Corporation $CVS

Key Points

• Groupe la Française acquired 50,024 CVS Health shares during the second quarter, valued at approximately $5.17 million. Institutional investors collectively own 80.66% of the company.
• CVS Health reported quarterly EPS of $2.58, exceeding estimates of $1.87, while revenue rose 7.3% year over year to $106.1 billion. The company issued fiscal 2026 EPS guidance of $7.90–$8.10.
• The company pays a quarterly dividend of $0.665, or $2.66 annually, representing a 2.7% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $106.83.

Groupe la Francaise bought a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,024 shares of the pharmacy operator's stock, valued at approximately $5,175,000.

Several other hedge funds also recently added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd raised its stake in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. purchased a new position in CVS Health during the fourth quarter valued at approximately $26,000. Kilter Group LLC purchased a new stake in CVS Health in the 2nd quarter worth approximately $27,000. Sankala Group LLC acquired a new position in shares of CVS Health in the 4th quarter valued at $28,000. Finally, Global Trust Asset Management LLC grew its position in CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 300 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

NYSE CVS opened at $96.80 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock's 50 day simple moving average is $100.65 and its 200-day simple moving average is $90.35. The company has a market cap of $123.80 billion, a PE ratio of 25.61, a price-to-earnings-growth ratio of 0.94 and a beta of 0.59. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The firm's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's dividend payout ratio (DPR) is currently 70.37%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CVS. Cantor Fitzgerald upped their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 7th. Wells Fargo & Company lifted their price target on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. HSBC reaffirmed a "hold" rating and issued a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Robert W. Baird set a $107.00 price target on CVS Health in a research report on Thursday, August 6th. Finally, Truist Financial boosted their price objective on CVS Health from $108.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, July 14th. Twenty-two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, CVS Health has an average rating of "Moderate Buy" and a consensus price target of $106.83.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.